147118-35-2

Basic information

• Product Name: Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate
• Synonyms: METHYL (3R)-3-(TERT-BUTYLDIMETHYL SILYLOXY)-5-OXO-6-TRIPHENYL PHOSPHORANYLIDENE HEXANOATE (J6);B-8 ;methyl-(3R)-3-[(terbutyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidene hexanoate;Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate;rosuvastatin interMediates J-6;(3R)-3-(tert-butyldiMethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate Methyl ester;Methyl (3R)-3-(tert-butyldiMethylsilyloxy)-5-oxo-6-triphenylphosphoranylidene hexanate;(R)-Methyl 3-((tert-butyldiMethylsilyl)oxy)-5-oxo-6-(triphenylphosphoranylidene)hexanoate
• CAS NO: 147118-35-2
• Molecular Formula: C₃₁H₃₉O₄PSi
• Molecular Weight: 534.7
• EINECS: 1312995-182-4
• Mol File: 147118-35-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 603.9 °C at 760 mmHg
• Flash Point: 319 °C
• Appearance: yellowish to white crystalline powder
• Density: 1.1 g/cm³
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate(147118-35-2)
• EPA Substance Registry System: Methyl (3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanoate(147118-35-2)

Safety Data

• Hazardous Substances Data: 147118-35-2(Hazardous Substances Data)

Usage

Uses

Methyl (3R)-3-(tert-Butyldimethylsilanyloxy)-5-oxo-6-(triphenylphosphanylidene)hexanoate was used to preapre pyrimidinyl- and pyrrolylheptenoates with HMG-CoA reductase inhibitory activities.

Upstream product

• 791-28-6 Triphenylphosphine oxide 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 91424-39-4 3-[[(1,1-Dimethylethyl)dimethylsilyl]-oxy]pentanedioic acid,diethyl ester 
• 32328-03-3 diethyl 3-hydroxyglutarate 
• 1779-49-3 Methyltriphenylphosphonium bromide 
• 1343494-42-7 (R)-3-((tert-butyldimethylsilyl)oxy)-5-(1H-imidazol-1-yl)-5-oxopentanoate methyl ester 
• 479070-41-2 methyl (R)-3-hydroxyhex-5-ynoate 
• 182681-88-5 (2R)-1-cyano-2-hydroxy-4-pentyne 
• 182681-86-3 (2R)-1-chloro-2-hydroxy-4-pentyne 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 79-22-1 methyl chloroformate 
• 1339958-09-6 C₁₃H₂₇IO₄Si 
• 1339957-98-0 C₁₃H₂₇BrO₄Si 
• 1337981-49-3 C₁₃H₂₇ClO₄Si 

Downstream Products

• 182075-76-9 (R,E)-methyl 3-(tert-butyldimethylsilyloxy)-7-(2-cyclopropyl-4-(-4-fluorophenyl)-quinolin-3-yl)-5-oxohept-6-enoate 
• 147118-39-6 methyl (3R,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3-hydroxy-5-oxohept-6-enoate 
• 1422619-13-3 7-[4-(4-fluorophenyl)-6-isopropyl-2(N-methyl-N-methanesulfonamido)pyrimidin-5-yl]-(3R)-3-hydroxy-5-carbonyl-6-(E)-heptenoic acid 
• 1374771-96-6 rosuvastatin, S-benzylisothiourea salt 
• 147118-40-9 (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid methyl ester 
• 287714-41-4 rosuvastatin 

Relevant articles and documents

Synthetic method for rosuvastatin intermediate

The invention discloses a synthetic method for a rosuvastatin intermediate and belongs to the field of medicine. The rosuvastatin intermediate is (3R)-tert-butyl dimethyl siloxyl-5-oxo-6-methyl triphenylphosphine caproate. According to the invention, (R)-3-tert-butyl dimethyl siloxyl-5-(1H-imidazole-1-group)-5-methyl oxoglutarate compound is taken as a raw material, is condensed with 5-methylsulfonyl-1-phenyl-1H-tetrazole and then reacts with phosphorus triphenyl oxide, so as to generate the (3R)-tert-butyl dimethyl siloxyl-5-oxo-6-methyl triphenylphosphine caproate. According to the invention, 5-methylsulfonyl-1-phenyl-1H-tetrazole is utilized to condense, so that the intermediate is stable; the detection is convenient; the phosphorus triphenyl oxide instead of triphenyl phosphine is usedas the raw material, so that the side product phosphorus triphenyl oxide of wittig reaction can be recycled; the process is simple and easy for industrialization.

Preparation method of novel rosuvastatin calcium intermediate

The invention provides a preparation method of a novel rosuavastatin calcium intermediate I which is suitable for industrial large-scale production. The preparation method comprises the step of enabling triphenyl methyl phosphorus bromide to react with a compound II, thus obtaining an intermediate I. The preparation method provided by the invention is safe and simple and is strong in operability, and a final finished product which is high in efficiency and purity can be obtained.

AN IMPROVED PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITOR INTERMEDIATES

The present invention relates to novel processes for the preparation of compounds of Formula-II useful as intermediates in preparation of HMG-CoA reductase inhibitors, and further conversion of said intermediates to HMG-CoA reductase inhibitors. The process for the preparation of compounds of Formula-II comprises reacting compounds of Formula-Ill with dimethylformamide dimethylacetal in the presence of a base to get compounds of Formula-IV, reacting the compounds of formula-IV with alkyl chloroformate in the presence of a base to get compounds of Formula-V, and converting the compounds of Formula-V into compounds of Formula-II. The compounds have the following structures, [Formulas should be inserted here] wherein X is hydrogen or hydroxy protecting group, R1 is carboxyl protecting group, Alk represents C1-C4 alkyl and R2, R3 and R4 are independently selected from substituted or unsubstituted C6-C10 aryl groups.